NASDAQ: RPTX

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors